89bio Aims to Tame NASH and Severe Hypertriglyceridemia (SHTG) with Lead Asset Pegozafermin
Update: 2022-11-11
Description
As the American obesity issue grows, the NASH and SHTG treatment markets concurrently expand. At 89bio, the idea is to use nature itself to therapeutically treat this growing problem. Using their lead asset pegozafermin, an analog of the endogenous hormone fibroblast growth factor 21 (FGF21), to restore metabolic homeostasis and thereby reduce liver fat, as well as triglyceride levels, 89bio is currently advancing their development program in both diseases. Tune in as CEO Rohan Palekar gives updates from the ENLIVEN study for NASH and ENTRIGUE study for SHTG, along with future directions in clinical development.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
